Tempest Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Tempest Therapeutics, Inc. (TPST) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-30
- Tempest Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.40%.
- Tempest Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 0.00%.
- Tempest Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was -2.40%.
- Tempest Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2019 was -1.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | -0.40% 10-K · filed 2026-03-30 | ||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-30 | ||
| 2020-12-31 | -2.40% 10-K · filed 2021-03-29 | ||
| 2019-12-31 | -1.00% 10-K · filed 2021-03-29 | ||
| 2018-12-31 | -4.10% 10-K · filed 2020-03-11 | ||
| 2017-12-31 | -26.60% 10-K · filed 2019-04-01 | -7.60% 10-K · filed 2018-03-15 | |
| 2016-12-31 | -2.66% 10-K · filed 2018-03-15 | ||
| 2015-12-31 | -8.15% 10-K · filed 2018-03-15 | ||
| 2014-12-31 | -0.27% 10-K · filed 2017-03-02 | -0.55% 10-K · filed 2015-03-16 | |
| 2013-12-31 | -0.92% 10-K · filed 2016-02-26 | -1.09% 10-K · filed 2014-02-27 | |
| 2012-12-31 | -2.78% 10-K · filed 2015-03-16 | ||
| 2011-12-31 | -3.93% 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |